Melatonin leads to improvement in markers of glycemic control, cardiometabolic risk, and oxidative stress in diabetic people receiving dialysis

This was a small (N=60) randomized, double-blind placebo controlled trial in adults with diabetes. Participants were randomized to receive either Melatonin 10mg QHS, or a placebo, for 12 weeks. A total of 53 people completed the study (26 in the melatonin group and 27 in the placebo group).

At the completion of the 12 week trial, people who received melatonin experienced the following statistically significant changes:

• Decreased FBS (P < .001)
• Decreased serum insulin levels (P = .01)
• Decreased hsCRP (P = .001)
• Increased plasma total antioxidant capacity (P <.001)
• Downregulated expression of IL-8 and TNFα, and reduced expression of PPAR-γ (P = .03, P= .008, and P = .03 respectively)

Melatonin was not found to significantly impact GSH or lipid levels in this trial. Melatonin supplementation was found to be well-tolerated, with no adverse events reported. Participants in the melatonin group also experienced significantly improved sleep function as measured by PSQI (P= .007).

Citation:

Ostadmohammadi V et al. The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Renal Nutrition 2019 Oct 6. pii: S1051-2276(19)30313-9

Link:

https://www.jrnjournal.org/article/S1051-2276(19)30313-9/abstract